Braeburn Inc., also known as Braeburn Pharmaceuticals, is a biopharmaceutical company dedicated to developing and commercializing innovative long-acting implantable and injectable medications. The company primarily focuses on treatments for opioid use disorder (OUD) and other central nervous system (CNS) disorders, including pain, schizophrenia, and spasticity.
Braeburns product portfolio features advanced delivery technologies such as ProNeura, FluidCrystal, and MedLaunch. Notable products include Probuphine, a six-month implantable treatment for opioid addiction, and CAM2038, which offers weekly and monthly buprenorphine formulations. The company is committed to addressing unmet needs in specialty CNS markets and emphasizes community engagement and patient-centered insights to support recovery. Braeburn ...
Braeburn Inc., also known as Braeburn Pharmaceuticals, is a biopharmaceutical company dedicated to developing and commercializing innovative long-acting implantable and injectable medications. The company primarily focuses on treatments for opioid use disorder (OUD) and other central nervous system (CNS) disorders, including pain, schizophrenia, and spasticity.
Braeburns product portfolio features advanced delivery technologies such as ProNeura, FluidCrystal, and MedLaunch. Notable products include Probuphine, a six-month implantable treatment for opioid addiction, and CAM2038, which offers weekly and monthly buprenorphine formulations. The company is committed to addressing unmet needs in specialty CNS markets and emphasizes community engagement and patient-centered insights to support recovery. Braeburn aims to establish long-acting treatment options as standards of care while fostering a culture of diversity, equity, and inclusion.
-
Number of Employees:
100-250
-
Annual Revenue:
$10-50 Million